Missä ja miksi sydämen vaajatoimintapotilaita tulisi seurata?

Teema : sydämen vajaatoiminta

Miten varautua sydänsiirteiden uhkaavaan vajeeseen?

Teema : elinsiirrot. English summar

Vasemman kammion mekaaninen tukihoito : siltahoito tai vaihtoehto sydämensiirrolle

Sydämen vajaatoiminnan osuus ihmisten sairastuvuudessa ja kuolleisuudessa on edelleen merkittävä lääke- ja muun hoidon kehityksestä huolimatta. Sydämensiirto on paras loppuvaiheen vaikeaa sydämen vajaatoimintaa sairastavan potilaan hoitomuoto, kun mikään muu hoito ei auta. Sydämensiirtojen määrää rajoittaa kuitenkin pula siirrännäisistä. Aikaisemmin verenkierron mekaanista tukihoitoa käytettiin lyhytaikaisena siltahoitona vajaatoiminnan ­loppuvaiheesta sydämensiirtoon. Viime vuosina tapahtunut kehitys on moninkertaistunut verenkierron mekaanisen tukihoidon käytön vaikeassa sydämen vajaatoiminnassa siltahoitona tai vaihtoehtona sydämensiirrolle. Mekaanisesti sydämen vasenta kammiota ja systeemiverenkiertoa tukevasta hoidosta saattaa tulla merkittävä vaihtoehto sydämensiirrolle, sillä tarkasti valikoiduilla potilailla kahden vuoden elinajan ennuste lähentelee sydämensiirtopotilaiden ennustetta.Peer reviewe

Outcomes after coronary artery bypass grafting and percutaneous coronary intervention in diabetic and non-diabetic patients

AimsTo assess the prognosis of patients with coronary heart disease (CHD) after first myocardial revascularisation procedure in real world practice and to compare the differences in outcomes of coronary artery by-pass grafting (CABG) and percutaneous coronary intervention (PCI) among diabetic and non-diabetic patients.Methods and resultsA database was compiled from the national hospital discharge register to collect data on all cardiac revascularisations performed in Finland in 2000-2015. The outcomes (all-cause deaths, cardiovascular (CV) deaths, major CV events and need for repeat revascularisation) after the first revascularisation were identified from the national registers at 28-day, 1-year and 3-year time points.A total of 139,242 first-time revascularisations (89,493 PCI and 49,749 CABG) were performed during the study period. Of all the revascularized patients, 24% had diabetes, and 76% were non-diabetic patients. At day 28 the risk of fatal outcomes was lower after PCI than after CABG among non-diabetic patients, whereas no difference was seen among diabetic patients. In long-term follow-up the situation was reversed with PCI showing higher risk compared with CABG for most of the outcomes. In particular, at three-year follow-up the risk of all-cause deaths was elevated among diabetic patients (HR 1.30 (95% CI 1.22-1.38) comparing PCI with CABG) more than among non-diabetic patients (HR 1.09 (1.04-1.15)). The same was true for CV deaths (HR 1.29 (1.20-1.38) among diabetic patients, and HR 1.03 (0.98-1.08) among non-diabetic patients).ConclusionAlthough PCI was associated with better 28-day prognosis, CABG seemed to produce better long-term prognosis especially among diabetic patients.</p

Peak flow measurements in patients with severe aortic stenosis : a prospective comparative study between cardiovascular magnetic resonance 2D and 4D flow and transthoracic echocardiography

Background Aortic valve stenosis (AS) is the most prevalent valvular disease in the developed countries. Four-dimensional (4D) flow cardiovascular magnetic resonance (CMR) is an emerging imaging technique, which has been suggested to improve the evaluation of AS severity compared to two-dimensional (2D) flow and transthoracic echocardiography (TTE). We investigated the reliability of CMR 2D flow and 4D flow techniques in measuring aortic transvalvular peak systolic flow in patients with severe AS. Methods We prospectively recruited 90 patients referred for aortic valve replacement due to severe AS (73.3 +/- 11.3 years, aortic valve area 0.7 +/- 0.1 cm(2), and 54/36 tricuspid/bicuspid), and 10 non-valvular disease controls. All the patients underwent echocardiography and 2D flow and 4D flow CMR. Peak flow velocity measurements were compared using Wilcoxon signed rank sum test and Bland-Altman analysis. Results 4D flow underestimated peak flow velocity in the AS group when compared with TTE (bias - 1.1 m/s, limits of agreement +/- 1.4 m/s) and 2D flow (bias - 1.2 m/s, limits of agreement +/- 1.6 m/s). The differences between values obtained by TTE (median 4.3 m/s, range 2.7-6.1 m/s) and 2D flow (median 4.5 m/s, range 2.9-6.5 m/s) compared to 4D flow (median 3.1 m/s, range 1.7-5.1 m/s) were significant (p < 0.001). The difference between 2D flow and TTE were insignificant (bias 0.07 m/s, limits of agreement +/- 1.5 m/s). In non-valvular disease controls, peak flow velocity was measured higher by 4D flow than 2D flow (1.4 m/s, 1.1-1.7 m/s and 1.3 m/s, 1.1-1.5 m/s, respectively; bias 0.2 m/s, limits of agreement +/- 0.16 m/s). Conclusions CMR 4D flow significantly underestimates systolic peak flow velocity in patients with severe AS. 2D flow, in turn, estimated the AS velocity accurately, with measured peak flow velocities comparable to TTE.Peer reviewe

Acute coronary syndromes and acute heart failure:a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology

Acute coronary syndrome is a precipitant of acute heart failure in a substantial proportion of cases, and the presence of both conditions is associated with a higher risk of short-term mortality compared to acute coronary syndrome alone. The diagnosis of acute coronary syndrome in the setting of acute heart failure can be challenging. Patients may present with atypical or absent chest pain, electrocardiograms can be confounded by pre-existing abnormalities, and cardiac biomarkers are frequently elevated in patients with chronic or acute heart failure, independently of acute coronary syndrome. It is important to distinguish transient or limited myocardial injury from primary myocardial infarction due to vascular events in patients presenting with acute heart failure. This paper outlines various clinical scenarios to help differentiate between these conditions and aims to provide clinicians with tools to aid in the recognition of acute coronary syndrome as a cause of acute heart failure. Interpretation of electrocardiogram and biomarker findings, and imaging techniques that may be helpful in the diagnostic work-up are described. Guidelines recommend an immediate invasive strategy for patients with acute heart failure and acute coronary syndrome, regardless of electrocardiographic or biomarker findings. Pharmacological management of patients with acute coronary syndrome and acute heart failure should follow guidelines for each of these syndromes, with priority given to time-sensitive therapies for both. Studies conducted specifically in patients with the combination of acute coronary syndrome and acute heart failure are needed to better define the management of these patients

Elinsiirrot - ei pelkkää kirurgiaa

Teema : elinsiirro